Research Analysts Offer Predictions for DNTH FY2024 Earnings

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) – HC Wainwright reduced their FY2024 earnings per share (EPS) estimates for Dianthus Therapeutics in a research note issued on Monday, November 11th. HC Wainwright analyst S. Ramakanth now expects that the company will earn ($3.06) per share for the year, down from their previous estimate of ($2.33). HC Wainwright currently has a “Buy” rating and a $40.00 target price on the stock. The consensus estimate for Dianthus Therapeutics’ current full-year earnings is ($2.61) per share. HC Wainwright also issued estimates for Dianthus Therapeutics’ Q4 2024 earnings at ($1.14) EPS, Q1 2025 earnings at ($1.21) EPS, Q2 2025 earnings at ($1.29) EPS, Q3 2025 earnings at ($1.06) EPS, Q4 2025 earnings at ($0.91) EPS, FY2025 earnings at ($4.47) EPS, FY2026 earnings at ($4.89) EPS, FY2027 earnings at ($4.61) EPS and FY2028 earnings at ($3.94) EPS.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.15). Dianthus Therapeutics had a negative return on equity of 21.68% and a negative net margin of 1,250.32%. The business had revenue of $2.17 million during the quarter, compared to analysts’ expectations of $1.07 million.

DNTH has been the subject of several other research reports. Oppenheimer raised their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research report on Monday, November 11th. Raymond James raised their target price on Dianthus Therapeutics from $51.00 to $56.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Baird R W upgraded Dianthus Therapeutics to a “strong-buy” rating in a research report on Friday, July 26th. Robert W. Baird started coverage on Dianthus Therapeutics in a research report on Friday, July 26th. They set an “outperform” rating and a $58.00 target price for the company. Finally, Wedbush cut their price objective on Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating for the company in a research report on Friday, August 9th. Eight equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Stock Performance

Shares of NASDAQ DNTH opened at $23.36 on Thursday. The firm has a market cap of $691.46 million, a price-to-earnings ratio of -9.34 and a beta of 1.84. The business’s 50-day simple moving average is $27.58 and its 200-day simple moving average is $26.64. Dianthus Therapeutics has a 52 week low of $6.58 and a 52 week high of $33.77.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Bain Capital Life Sciences Investors LLC acquired a new stake in Dianthus Therapeutics during the 1st quarter worth about $89,761,000. RA Capital Management L.P. acquired a new stake in Dianthus Therapeutics during the 1st quarter worth about $69,990,000. State Street Corp grew its holdings in Dianthus Therapeutics by 101.4% during the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock worth $22,483,000 after acquiring an additional 413,425 shares during the period. Vanguard Group Inc. grew its holdings in Dianthus Therapeutics by 250.0% during the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock worth $16,135,000 after acquiring an additional 384,182 shares during the period. Finally, Janus Henderson Group PLC acquired a new stake in Dianthus Therapeutics during the 1st quarter worth about $11,251,000. 47.53% of the stock is currently owned by institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.